Evolus Stock Price, News & Analysis

Evolus (NASDAQ: EOLS) has received two prestigious Shape 2025 Skin Awards for its recently launched Evolysse™ injectable hyaluronic acid gel line and Club Evolus™ rewards program. Evolysse™ was named Best Filler for 2025, while Club Evolus™ won for Best Membership Treatment Model. The recognition comes shortly after the FDA approval of Evolysse™ Form and Evolysse™ Smooth in February 2025 and their U.S. launch in April. The products feature innovative Cold-X™ technology designed to maintain the natural structure of hyaluronic acid for enduring, natural-looking results. The awards were selected from over 800 products and treatments by a panel of board-certified dermatologists and specialists, validating Evolus' strategy in the injectable HA category and its consumer-focused approach through the Club Evolus™ digital loyalty platform.

Evolus (NASDAQ: EOLS) announced that CFO Sandra Beaver will resign effective June 13, 2025, to join a private mental health and wellness technology company. Her departure is not related to any disagreements regarding company operations, policies, or practices. CEO David Moatazedi highlighted recent company achievements, including the launch of a second product line, record revenues, improved balance sheet, and positioning for profitability. The company has initiated a search for Beaver's successor, with the current Finance team managing operations during the transition period.

Evolus (NASDAQ: EOLS) announced the publication of U.S. pivotal study results for Evolysse™ Form and Evolysse™ Smooth in the Aesthetic Surgery Journal. The study evaluated these Cold-X™ crosslinked injectable hyaluronic acid gels for facial wrinkle correction. Key findings showed both products demonstrated statistical superiority over Restylane®-L, with Evolysse™ Form showing significant differences throughout the 12-month study period. Evolysse™ Smooth achieved better results with 20% less product used. The study reported over 80% patient satisfaction and a favorable safety profile with no treatment-related serious adverse events. Additionally, Evolus received EU MDR approval for four injectable HA gels under the brand name Estyme®, with a broader European launch planned for H2 2025.

Evolus (NASDAQ: EOLS) has granted equity incentives to 16 newly hired non-executive employees in May 2025. The compensation package includes 12,706 non-qualified stock options with an exercise price of $9.98 per share and 40,576 restricted stock units (RSUs). The stock options have a 10-year term and vest over 4 years, with 25% vesting annually. Similarly, the RSUs vest 25% each year. These awards were approved under the Evolus 2023 Inducement Incentive Plan, with a grant date of May 12, 2025, and vesting commencement date of May 7, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).

Evolus (NASDAQ: EOLS) reported strong Q1 2025 financial results with global net revenue of $68.5 million, up 15.5% year-over-year. The company posted a GAAP operating loss of $15.2 million and a non-GAAP operating loss of $5.5 million. Despite operating in a slower market, Evolus gained meaningful market share and successfully launched Evolysse™ in Q2.

Key highlights include: over 16,000 total customers with a 70% reorder rate, Evolus Rewards™ program growing to over 1.1 million members (39% YoY increase), and record-high quarterly redemptions exceeding 220,000. The company reaffirmed its 2025 revenue guidance of $345-355 million, with Evolysse™ and Estyme® expected to contribute 8-10% of total revenue.

Looking ahead, Evolus projects reaching $700 million in revenue by 2028 (27% CAGR from 2024) and achieving non-GAAP operating income margins of at least 20% by 2028.

Evolus (NASDAQ: EOLS) has successfully refinanced its credit facility, replacing the existing $125 million agreement with a new $250 million facility managed by Pharmakon Advisors. The new facility features a 350 basis points reduction in borrowing costs, with interest at 3-month SOFR plus 5.00% per annum and a five-year maturity. The structure includes a $150 million initial draw and two additional optional tranches of $50 million each available through December 2026.

Key improvements include conversion from amortizing to bullet maturity payment, reduced prepayment fees, and increased financial flexibility. The refinancing eliminates the need for principal payments in 2026 and provides enhanced working capital flexibility to support commercial momentum and strategic initiatives.

Evolus (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio of consumer brands, has scheduled its first quarter 2025 financial results announcement for Wednesday, May 7, 2025, after U.S. market close.

Management will host a conference call and webcast at 4:30 p.m. ET the same day, including a Q&A session. Participants can join via phone at (800) 579-2543 (U.S.) or (785) 424-1789 (international), or through the live webcast on the company's Investor Relations webpage.

Evolus (NASDAQ: EOLS) has announced the granting of 30,579 restricted stock units (RSUs) to 13 newly hired non-executive employees under its 2023 Inducement Incentive Plan. The grants were approved by the company's compensation committee as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4).

The RSUs have a grant date and vesting commencement date of April 7, 2025, with 25% vesting on each annual anniversary. The awards are contingent upon continuous employment through each vesting date and are subject to the terms of the 2023 Inducement Incentive Plan and respective agreements.

Evolus (NASDAQ: EOLS) has announced the commercial launch of Evolysse™ Form and Evolysse™ Smooth injectable hyaluronic acid (HA) gels, scheduled for April 18th. The launch includes an early experience program with over 1,000 key accounts and a national Evolus Academy webcast.

The Evolysse™ collection represents the company's second commercial aesthetics product after Jeuveau®, which has achieved over 14% U.S. market share and penetration in 50% of aesthetic clinics. The new products utilize innovative Cold-X™ technology for treating facial wrinkles and folds.

In clinical trials against Restylane®-L, both Evolysse™ products demonstrated statistical superiority at the 6-month primary endpoint. Evolysse™ Form showed significant differences throughout the 12-month study period, while Evolysse™ Smooth showed significant differences at 6 and 9 months, despite using 20% less product than Restylane®-L.